Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN) bags another milestone payment
Published by Arron Aatkar, PhD

Basilea has received a US$25m milestone payment from Pfizer, its license partner in Europe, triggered by the strong sales performance of lead antifungal asset Cresemba in this region. Multiple milestone payments have been announced this year for exceeding sales thresholds in the Asia-Pacific region and China, reflecting the sustained market traction for Cresemba across the globe, and further significant milestones are anticipated in H224. According to management, total global in-market sales of Cresemba amounted to US$489m in the 12 months between April 2023 and March 2024, representing 24% growth year-on-year.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.